A study reported in the immunotherapy space suggested not all immune checkpoint inhibitor side effects are equal for survival. The work challenges the common clinical interpretation that adverse events necessarily correlate with better outcomes, implying clinicians may need more nuanced risk–benefit thinking when managing toxicity. In another checkpoint-adjacent update, researchers proposed a blood biomarker—soluble PD-1—to flag post-liver-transplant recurrence risk in immunotherapy-bridged hepatocellular carcinoma. Using samples taken the day before surgery, the study found that higher pretransplant sPD-1 concentrations separated recurrence vs recurrence-free trajectories. Taken together, the findings push biomarker development beyond “yes/no” toxicity signals toward measurable immunobiology tied to durable response and recurrence.